A-101
A-101-WART-301
Phase 3 small_molecule completed
Quick answer
A-101 for Common Wart is a Phase 3 program (small_molecule) at Aclaris Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Aclaris Therapeutics
- Indication
- Common Wart
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed